AVITA Medical (RCEL) Expected to Announce Earnings on Thursday

AVITA Medical (NASDAQ:RCEL) is projected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect AVITA Medical to post earnings of ($0.33) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). The firm had revenue of $18.41 million for the quarter, compared to analyst estimates of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AVITA Medical Trading Down 1.2 %

Shares of NASDAQ:RCEL opened at $10.22 on Thursday. The company has a 50 day moving average of $10.51 and a 200-day moving average of $10.62. The firm has a market cap of $267.97 million, a P/E ratio of -4.28 and a beta of 1.55. AVITA Medical has a twelve month low of $7.51 and a twelve month high of $18.93. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39.

Analyst Ratings Changes

RCEL has been the topic of a number of research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of AVITA Medical in a report on Friday, February 14th. Piper Sandler restated a “neutral” rating and set a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Finally, Lake Street Capital reduced their price target on shares of AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, AVITA Medical currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.